As reported in lung cancer, we suggested that EGFR alteration could be a potential oncogenic driver, so in February 2024, osimertinib (80 mg daily), a third-generation EGFR tyrosine kinase inhibitor, was started as a second-line treatment. The gene discussed is EGFR; the disease is lung carcinoma.